Ropivacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Silodosin can be increased when it is combined with Buprenorphine. Chlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ethyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Brompheniramine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Methylnaltrexone. Cinchocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Doxepin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Buprenorphine can be decreased when it is combined with Boceprevir. The serum concentration of Buprenorphine can be decreased when it is combined with Bosentan. Norflurane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Moclobemide. Clidinium may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Proparacaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Thiamylal may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Methohexital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Mecamylamine is combined with Buprenorphine. Trans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Ergotamine is combined with Buprenorphine. The serum concentration of Cerivastatin can be increased when it is combined with Buprenorphine. Perphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Tolcapone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Morphine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Crisaborole. Loprazolam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Diltiazem. Phentermine may increase the analgesic activities of Buprenorphine. Loxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Difenoxin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Meprobamate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Dezocine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Cicletanine. Clonazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. 4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Buprenorphine. The serum concentration of Tizanidine can be increased when it is combined with Buprenorphine. Iloperidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Betaxolol. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mebanazine. Propericiazine may increase the hypotensive activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Itraconazole. Adipiplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Quazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Clarithromycin. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Methyclothiazide. The risk or severity of adverse effects can be increased when Ergonovine is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Mirabegron. Etifoxine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Telithromycin. The metabolism of Buprenorphine can be decreased when combined with Artemether. The risk or severity of adverse effects can be increased when Buprenorphine is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline. Cocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Fluphenazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Rosiglitazone. Indiplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Fluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Harmaline. Flupentixol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Buprenorphine. BL-1020 may increase the hypotensive activities of Buprenorphine. Ondansetron may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Chlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Allopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Phenelzine. The metabolism of Buprenorphine can be decreased when combined with Nicardipine. The serum concentration of Buprenorphine can be decreased when it is combined with Enzalutamide. The metabolism of Buprenorphine can be decreased when combined with Indinavir. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Alvimopan. Carbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Iproniazid. Amobarbital may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Topotecan can be increased when it is combined with Buprenorphine. Mephedrone may increase the analgesic activities of Buprenorphine. Pimozide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Levodopa may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Zopiclone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Vigabatrin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Crizotinib. Nitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Pivhydrazine. Buprenorphine may increase the serotonergic activities of Escitalopram. The metabolism of Buprenorphine can be decreased when combined with Trimethoprim. Alfaxalone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Tropicamide is combined with Buprenorphine. Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Trans-2-Phenylcyclopropylamine. The metabolism of Buprenorphine can be decreased when combined with Fosamprenavir. Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Pitavastatin can be increased when it is combined with Buprenorphine. Flunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Imatinib. Alfentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Pipotiazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Butamben may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Clobazam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Canrenoic acid. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Minaprine. Lidocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Tandospirone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Lorcaserin. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone. The metabolism of Buprenorphine can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Buprenorphine. Thiethylperazine may increase the hypotensive activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Gemfibrozil. Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Mannitol. Meclizine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. Fluspirilene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Clopamide. Ethosuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Ticrynafen. The risk or severity of adverse effects can be increased when Tubocurarine is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Umeclidinium is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Furazolidone. The risk or severity of adverse effects can be increased when Buprenorphine is combined with Bumetanide. The metabolism of Buprenorphine can be decreased when combined with Tolbutamide. The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Sildenafil. Methadone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The metabolism of Buprenorphine can be decreased when combined with Lopinavir. Ziprasidone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The serum concentration of Ledipasvir can be increased when it is combined with Buprenorphine. The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Buprenorphine. Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.